Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Leiomyoma 8Prostatic Neoplasms 5Menorrhagia 5Myofibroma 2Prostate Adenocarcinoma 1Endometriosis 1

Interventions

estradiol, norethindrone drug combination 7asoprisnil 6relugolix 5Estradiol 5elagolix 4vilaprisan 3Norethindrone Acetate 3linzagolix 2Uterine Artery Embolization 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Hysterectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Menorrhagia × relugolix × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

NCT03751124 2024-06-25

Study of Relugolix With Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences GmbH

Phase 3 Completed
229 enrolled 66 charts

Leiomyoma, Menorrhagia, Myofibroma

NCT03412890 2024-05-09

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences GmbH

Phase 3 Completed
477 enrolled 27 charts

Leiomyoma, Menorrhagia

NCT03103087 2022-04-20

LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences GmbH

Phase 3 Completed
382 enrolled 57 charts

Leiomyoma, Menorrhagia

NCT03049735 2022-04-19

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences GmbH

Phase 3 Completed
388 enrolled 54 charts

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡